Showing results (21-30 of 136) with videos related to
Sort By:
Pageof 14
BMC Health Services Research|June 2, 2018
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisalsLiz Morrell, Sarah Wordsworth, Anna Schuh, et al.BMC Health Services Research|March 30, 2019
Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisalsLiz Morrell, Sarah Wordsworth, Anna Schuh, et al.British Journal of Cancer|July 28, 2020
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectivesMark R Middleton, Christoph Hoeller, Olivier Michielin, et al.Cancer|February 1, 2008
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinionAxel Hauschild, Helen Gogas, Ahmad Tarhini, et al.European Journal of Cancer (Oxford, England : 1990)|May 8, 2020
Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanomaMatthew Hemstock, Adenike Amadi, Katrin Kupas, et al.BMC Cancer|October 19, 2017
Societal preferences for adjuvant melanoma health states: UK and AustraliaMark R Middleton, Michael B Atkins, Kaitlan Amos, et al.Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|April 25, 2014
Individual risk modelling for esophagectomy: a systematic reviewJohn M Findlay, Richard S Gillies, Bruno Sgromo, et al.International Journal of Cancer|July 19, 2002
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft modelMark R Middleton, Nicholas Thatcher, T Brian H McMurry, et al.Melanoma Research|June 30, 2009
Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cellsAmi Sabharwal, Rachel Waters, Sarah Danson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2011
New challenges in endpoints for drug development in advanced melanomaAntoni Ribas, Peter Hersey, Mark R Middleton, et al.Pageof 14